Literature DB >> 24325909

Genetic variation rs10484761 on 6p21.1 derived from a genome-wide association study is associated with gastric cancer survival in a Chinese population.

Meiyun Kang1, Xiaojie Ding1, Ming Xu1, Haixia Zhu2, Sang Liu1, Meilin Wang1, Dongmei Wu1, Na Tong1, Weida Gong3, Jianwei Zhou4, Zhengdong Zhang5.   

Abstract

A recent genome-wide association study (GWAS) on esophageal squamous-cell carcinoma (ESCC) among Chinese people has discovered a novel single nucleotide polymorphism (SNP) rs10484761 on 6p21.1 region. We hypothesized that SNP rs10484761 T/C is associated with survival of gastric cancer. We genotyped SNP rs10484761 in 940 gastric cancer patients treated with surgical resection. Kaplan-Meier survival analysis, log-rank test, and Cox proportional hazard models were used to evaluate the association between the SNP rs10484761 and gastric cancer survival. In the dominant model, those who carry TC/CC genotypes had a significant shorter survival time (log-rank P=0.005), especially in the subgroups of aged male patients, cardia intestinal tumor (HR=1.41, 95% CI=1.08-1.84 for cardia cancer and HR=1.64, 95% CI=1.14-2.37 for intestinal-type), tumor size ≤ 5 cm (HR=1.41, 95% CI=0.56-0.99), T1 depth invasion (HR=2.34, 95% CI=1.20-4.56), lymph node metastasis (HR=1.51, 95% CI=1.19-1.96), no distant metastasis (HR=1.33, 95% CI=1.05-1.68), TNM stage III+IV (HR=1.50, 95% CI=1.13-1.98), and with chemotherapy (HR=1.53, 95% CI=1.17-1.99). The results indicated that SNP rs10484761 was associated with prognosis of gastric cancer, suggesting that this genetic variant may serve as a potential marker to predict the survival of gastric cancer in Chinese population.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  95% CI; 95% confidence interval; ESCC; GC; GENe Expression VARiation; GWAS; Gastric cancer; Genevar; HR; LD; MST; Polymorphism; SNP; Survival; TNM; eQTL; esophageal squamous-cell carcinoma; expression quantitative trait loci; gastric cancer; genome-wide association study; hazard ratio; linkage disequilibrium; median survival time; single nucleotide polymorphism; tumor-node-metastasis

Mesh:

Year:  2013        PMID: 24325909     DOI: 10.1016/j.gene.2013.11.087

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Association of vascular endothelial growth factor expression and polymorphisms with the risk of gestational diabetes mellitus.

Authors:  Ping-Ping Dong
Journal:  J Clin Lab Anal       Date:  2018-10-23       Impact factor: 2.352

2.  Variants identified by hepatocellular carcinoma and chronic hepatitis B virus infection susceptibility GWAS associated with survival in HBV-related hepatocellular carcinoma.

Authors:  Cong Li; Xinyu Bi; Ying Huang; Jianjun Zhao; Zhiyu Li; Jianguo Zhou; Meng Zhang; Zhen Huang; Hong Zhao; Jianqiang Cai
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

3.  Genetic polymorphism of rs9564966 G > A on 13q22.1 predicts poor survival for Chinese patients with gastric cancer.

Authors:  Tingting Zhao; Xinying Huo; Jinfei Chen
Journal:  Cancer Med       Date:  2018-12-08       Impact factor: 4.452

4.  AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer.

Authors:  Xi Liu; Zhaoxia Li; Yue Song; Rui Wang; Lei Han; Qixue Wang; Kui Jiang; Chunsheng Kang; Qingyu Zhang
Journal:  Oncotarget       Date:  2016-05-31

5.  Identification of polymorphisms in cancer patients that differentially affect survival with age.

Authors:  Aoife Doherty; Yelena Kernogitski; Alexander M Kulminski; João Pedro de Magalhães
Journal:  Aging (Albany NY)       Date:  2017-10-20       Impact factor: 5.682

6.  Intronic polymorphisms in genes LRFN2 (rs2494938) and DNAH11 (rs2285947) are prognostic indicators of esophageal squamous cell carcinoma.

Authors:  Jiru Wang; Qiuzi Wang; Bin Wei; Yu Zhou; Zhaoye Qian; Yong Gao; Xiaofei Chen
Journal:  BMC Med Genet       Date:  2019-05-03       Impact factor: 2.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.